<div id="readability-page-1"><div>By Jason Chau Shares of Takeda Pharmaceuticals rose after the Japanese pharmaceutical major announced positive results from clinical trials of its new treatment for plaque psoriasis. The stock climbed 4.3% in early Tokyo trade Friday to reach a three-month high before pulling back slightly. It is on course for its biggest single-day gain since April. The benchmark Nikkei Stock Average was last up 1.2%. Takeda's gains came after it said its drug candidate zasocitinib delivered positive results in Phase 3 studies, the final stage of clinical trials before regulatory approval. The new drug is designed to treat moderate to severe plaque psoriasis, a condition that causes raised, itchy and painful skin patches covered by scales. An estimated 64 million people globally have psoriasis with 80%-90% of them having plaque psoriasis specifically, medical studies show. The drug, delivered in a once-a-day pill, achieved complete or near-complete clearance of skin lesions in more than half of the trial participants, Takeda said Thursday. The drugmaker said it plans to submit a new drug application with the U.S. Food and Drug Administration in the 2026 fiscal year. &#34;[The results represent] best-in-class data and leaves quite a positive impression, as we believe expectations for the drug were not particularly high,&#34; said Citi Research analyst Hidemaru Yamaguchi in a note. The bank forecasts annual sales of 150 billion yen, or $964.3 million, for the drug, with its launch expected in the fiscal year ending March 2027. Write to Jason Chau at jason.chau@wsj.com (END) Dow Jones Newswires12-18-25 2232ET</div></div>

4502

泰凱達製藥的股票在東京早盤交易中上漲了 4.3%，原因是該公司宣佈其新型銀屑病治療藥物 zasocitinib 的第三階段臨牀試驗結果積極。該藥物在治療斑塊型銀屑病方面顯示出顯著的療效，預計將在 2026 年前向 FDA 提交新藥申請。花旗研究預計該藥物的年銷售額將達到 1500 億日元，預計將在 2027 年 3 月前上市

武田製藥因銀屑病治療取得積極結果，股價上漲